Objectives This study aims to investigate the diagnostic and prognostic role of mean platelet volume (MPV) and MPV/platelet (PLT) ratio in the most common soft tissue sarcomas. Patients and methods We retrospectively investigated 131 patients (76 males, 55 females; mean age: 51.8±17.1; range, 18 to 87 years) with soft-tissue sarcomas between January 2011 and January 2019. Demographic features, MPV, PLT counts, mortality, and recurrence records of the patients were obtained from archives. A total of 165 healthy volunteers (101 males, 64 females; mean age 52.9±4.1; range, 18 to 60 years) who applied to the outpatient clinic in 2019 and had routine blood control without any additional disease formed the control group. Results A total of 55 patients were diagnosed with liposarcoma and 76 with pleomorphic sarcoma. Of the tumors, 77.1% were located in the lower limbs. Lesions were mostly localized on the thigh 48.8% (n=64). Recurrence occurred in 28.2% of the patients. A total of 25 (19.1%) patients were exitus. The mean follow-up period of the patients was 34.4±19.1 (range, 9 to 112) months. The mean PLT value of the patient group was significantly higher than the control group. The median MPV and MPV/PLT ratio were statistically significantly lower in the patient group than in the control group. The MPV and MPV/PLT ratio were not associated with mortality and recurrence. Conclusion As a result, MPV and MPV/PLT ratio can be used as a diagnostic support parameter in soft tissue sarcomas, but have no prognostic value.
ÖZAdamantinomalar nadir görülen low grade malign kemik tümörleridir. En sık 20-30 yaşlar arasında görülürler ve erkeklerde daha sık görülme eğilimindedirler. En sık yerleşim yeri tibiadır. Hastalar en sık ağrılı ya da ağrısız bir şişlik ile başvururlar. Radyografisi agresiftir. Tedavisi tümörün geniş rezeksiyonu ve rekonstrüksiyondur. Kemoterapi faydasızdır ve radioresistanttır. Uzun dönem sağkalımı iyidir. Bu çalışmada 17 yaşında erkek hastada tibia proksimal yerleşimli adamantinoma olgusunu sunduk. Başarılı tedavisi yapılan hasta halen takibimiz altındadır. ABSTRACTAdamantinomas are rare low grade malignant bone tumors. They are most common between the ages of 20 and 30 and are slightly more common in men. The most common localization is the tibia. The patients present with a painful or painless swelling and the lesion seems to be aggressive on radiography. The treatment is extensive resection of the tumor and reconstruction. Chemotherapy is useless as the lesions are radioresistant. The long term prognosis is good. In this study, we present a case of adamantinoma located at the proximal section of the tibia in a 17-year-old male patient. The treatment was successful and the patient is still under follow-up. GIRIŞAdamantinoma, mikroskobik olarak hafif bir iğ hücresiyle çevrili epitelial hücre kümeleriyle karakterize edilen düşük dereceli bir malign neoplazmdır (1). Tüm primer kemik tümörlerinin %1'inden azını oluşturan nadir bir tümördür (2).En sık görüldüğü yaş aralığı 20-50 yaş arasıdır ve erkeklerde daha sık görülür. Tibia, en çok etkilenen bölgedir (raporların %85'i) (3-6).En sık klinik bulgular sırasıyla ağrı ve lokalize şişliktir (7). Radyografisinde genellikle agresif bir pattern sergiler, yer yer radyolüsen alanlar içeren kötü sınırlı sklerotik bir lezyon görülür (8). Adamantinoma tedavisi lezyonun geniş rezeksiyonu ve kemik defektinin rekonstrüksiyonudur (9,10).Kemoterapi veya radyoterapinin tedavide yeri yoktur. Lokal rekürrens ve uzak metastaz nadirdir, metastaz gelişirse en sık akciğerlere gelişir (7,9,10).Biz bu çalışmada sağ tibia proksimali yerleşimli adamantinoması olan bir hastanın presentasyon, görüntüleme bulguları, tedavisi ve takibini tanımladık.
Objectives In this study, we present the characterization of tumors located in the fibula, which is a rare site for tumors, and the clinical and functional results of patients with fibular tumors that we operated in our clinic. Patients and methods Between February 2008 and December 2018, a total of 104 patients (58 males, 46 females; mean age: 26±18 years; range, 3 to 78 years) who were operated for tumor located in the fibula were retrospectively analyzed. Demographic data, histopathological diagnosis, tumor localization, surgical method and postoperative complications, metastases, follow-up time, and functional results of the patients were recorded. The fibula was divided into three groups as proximal, diaphysis and distal one-third. Results The mean follow-up was 56±25.3 (range, 24 to 108) months. Eighty (76.9%), seven (6.7%) and 17 (16.3%) patients were located proximal, diaphysis and distal to the fibula, respectively. The number of patients with malignant tumors located in the fibula was 26 (25%), the tumor was benign in 54 (51.9%) patients and 24 (23%) tumors were borderline. The most common tumor localized to the fibula was osteochondroma with 28 (26.9%) patients. The most common malignant tumors located in the fibula were Ewing sarcoma and osteosarcoma in 11 patients each. The most common surgical method was curettage in 44 (42.3%) patients. Distant organ metastases were present in 18 (17.3%) patients. The Musculoskeleteal Tumor Society score of 17 patients who underwent resection of the proximal fibula were 87%. Conclusion Fibula is a rare location for tumors and fibula tumors tend to be located more proximal. Tumors located in the fibula have good functional outcomes after surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.